Per Arvidsson

Platform Director, Karolinska Institutet

Drug Discovery and Development

Key publications

1. K. K. Rajbongshi, S. Ambala, T. Govender, H. G. Kruger, P. I. Arvidsson, T. Naicker, ”Microwave Accelerated N-Acylation of Sulfoximines with Aldehydes under Catalyst free conditions”
Synthesis, 2020, 52, 1279-1286 (10.1055/s-0039-1691589)

2. A. S. Dibavar, H. Gullberg, P. Sabatier, C. Beusch, K. Johansson, B. Lundgren, P. I. Arvidsson, E. S. J. Arnér, R. Zubarev, ”Comprehensive Chemical Proteomics for Target Deconvolution of the Redox Active Drug Auranofin”
Redox Biology, 2020, 32, 101491 (10.1016/j.redox.2020.101491)

3. P. K. Chinthakindi, A. Benediktsdottir, P. I. Arvidsson, Y. Chen, A. Sandström, “Solid Phase Synthesis of Sulfonimidamide Pseudopeptides and Library Generation”
Eur. J. Org. Chem. 2020, 25, 3796-3807 (10.1002/ejoc.202000108)

4. K. E. Carlström, P. K. Chinthakindi, B. Espinosa, F. Al Nimer, E. S. J. Arnér, P. I. Arvidsson, F. Piehl, K. Johansson, “Characterization of more Selective Central Nervous System Nrf2 Activating Novel Vinyl Sulfone compounds compared to Dimethyl fumarate”Neurotherapeutics 2020, 17, 1142-1152 (10.1007/s13311-020-00855-0)

5. N. Bonagas, N. M. S. Gustafsson, M. Henriksson, P. Marttila, R. Gustafsson, E. Wiita, S. Borhade, A. C. Green, K. S. A. Vallin, A. Sarno, R. Svensson, C. Göktürk, T. Pham, A. -S. Jemth, O. Loseva, V. Cookson, N. Kiweler, L. Sandberg, A. Rasti, J. E. Unterlass, M. Haraldsson, Y. Andersson, E. R. Scaletti, C. Bengtsson, C. B. J. Paulin, K. Sanjiv, E. Abdurakhmanov, L. Pudelko, B. Kunz, M. Desroses, P. Iliev, K. Färnegårdh, A. Krämer, N. Garg, M. Michel, S. Häggblad, M. Jarvius, C. Kalderén, A. Bögedahl Jensen, I. Almlöf, S. Karsten, S. M. Zhang, M. Häggblad, A. Eriksson, J. Liu, B. Glinghammar, N. Nekhotiaeva, F. Klingegård, T. Koolmeister, U. Martens, S. Llona-Minguez, R. Moulson, H. Nordström, V. Parrow, L. Dahllund, B. Sjöberg, I. L. Vargas, D. D. Vo, J. Wannberg, S. Knapp, H. E. Krokan, P. I. Arvidsson, M. Scobie, J. Meiser, P. Stenmark, U. Warpman Berglund, E. J. Homan, T. Helleday, ”Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress”
Nature Cancer 2022, 3, 156–172 (10.1038/s43018-022-00331-y)

Director, Drug Discovery & Development

The mission of DDD is to turn academic discoveries into innovations – prototype drugs – and to provide technologies and training for state-of-the-art drug discovery in Sweden. DDD has become a trustworthy, efficient, and internationally recognized professional national hub with a proven impact on Sweden ́s life science strategy. Since the start, DDD has supported progress of four drug discovery programs to clinical phase 1 studies, five to international partnerships, and nine to new Swedish biotech – some subsequently listed on Nasdaq First North Growth market (two during 2021).

Integration of DDD within the vibrant SciLifeLab environment offers access to novel complementary technologies and expertise that seldom are available even at large pharma companies. Among the host universities for DDD (UU, KI, KTH, SU, and LU), UU is the legal proxy. In the years to come, DDD will expand operations from the current five host universities to also include early-stage therapeutic oligonucleotide drug discovery at GU and strive to take a more active role in working together with tech transfer offices around Sweden for more efficient innovation.

Last updated: 2023-08-15

Content Responsible: Johan Inganni(